Xaira Therapeutics

Founded in 2024 and based in the San Francisco Bay Area, Xaira Therapeutics is a new but prominent biotechnology company that integrates artificial intelligence (AI) into drug development. The company was co-founded by Marc Tessier-Lavigne, known for his scientific and academic expertise, and David Baker, who is noted for his innovations at the University of Washington’s Institute of Protein Design. Xaira Therapeutics aims to advance the way drugs are developed by solving complex biological challenges through AI, enhancing how medicines are discovered and improving patient care.

NewsHeat chart

Week
Month
Year

Media news
Corp news

Click to unlock the chart

The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice

Company Valuation

Valuation
Share Price
Cumulative Funding

The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer.

Funding Round

Funding Amount

Post-Money Valuation

Share Price

Venture24 Apr, 2024

***

*** - To view the data, please log into your account or create a new one.

News related to Xaira Therapeutics3

Sort by

Xaira Therapeutics

Oct 17, 2024 •Show on chart

Xaira Therapeutics Appoints Dr. Debbie Law as Chief Scientific ...

Xaira Therapeutics today announced the appointment of Dr. Debbie Law and Julia Tran to its C-suite. Law will serve as chief scientific officer, and Tran will ...

https://www.morningstar.com/news/business-wire/20241017008524/xaira-therapeutics-appoints-dr-debbie-law-as-chief-scientific-officer-and-julia-tran-as-chief-people-officer

Xaira Therapeutics

Oct 17, 2024 •Show on chart